AI Structured Summary
Not yet generated for this judgment
Judgment
Prathiba M. Singh, J. (Oral)
This hearing has been done through hybrid mode.
It is already 5:15 p.m. No time left.
Vide order dated 1st August, 2024, this Court directed as follows:
“11.Further, Ms. Jain, ld. Counsel, also submits that there are two trials currently approved by the DCGI in India for DMD therapies. The details of the two trials have been handed over to Mr. Chawla, who is appearing for M/s Sarepta Therapeutics. Mr. Chawla, ld. Counsel, under instructions, submits that the recruitments for the said trials are closed. However, it appears from the document handed over by the DCGI that the total number of subjects recruited by M/s Sarepta Therapeutics is less than the approved number of Indian subjects to be enrolled.
12.Let an affidavit in this regard be filed by M/s Sarepta Therapeutic by the next date of hearing. In the affidavit, M/s. Sarepta shall also state as to whether the pricing of its medicines for DMD varies in different countries and if so a chart shall be filed giving the retail price at which the products are available both before and after discounts in at least 10 advanced countries and 10 developing countries including India’s neighbouring countries. Let the said affidavit be filed by 10th August 2024.”
On behalf of M/s Sarepta Therapeutics, it is submitted that the affidavit could not be placed on record. Let the same be brought on record in a sealed cover by the next date of hearing.
Directions issued to M/s Sarepta Therapeutics in paragraph 12 of the order dated 1st August, 2024 (extracted above) shall also be complied with by M/s Roche in respect of medicines for Spinal Muscular Atrophy (‘SMA’), bearing in mind the charts placed by Mr. Anand Grover, ld senior counsel. Let the said affidavit be also placed before the Court in a sealed cover by the next date of hearing.
List on 31st August, 2024 at 10:30 am for conclusion of submissions.
These are part-heard matters.